HL7 FHIR® Implementation Guide: Breast Cancer Data, Release 1 - US Realm (Draft for Comment)
This page is part of the Breast Cancer Data Logical Models and FHIR Profiles (v0.1.0: STU 1 Draft) based on FHIR R3. . For a full list of available versions, see the Directory of published versions 
BC OncotypeDxDCISRiskScoreInterpretationVS ValueSet
Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score
| Defining URL: | http://hl7.org/fhir/us/breastcancer/ValueSet/oncology-OncotypeDxDCISRiskScoreInterpretationVS |
| Name: | OncotypeDxDCISRiskScoreInterpretationVS |
| Definition: | Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score |
| Publisher: | The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC) |
| Source Resource | XML / JSON / Turtle |
This value set contains 3 concepts
Expansion based on http://hl7.org/fhir/us/breastcancer/CodeSystem/oncology-OncotypeDxDCISRiskScoreInterpretationCS version 0.1.0
All codes from system http://hl7.org/fhir/us/breastcancer/CodeSystem/oncology-OncotypeDxDCISRiskScoreInterpretationCS
| Code | Display | Definition |
| low_risk | Recurrence Score lower than 38: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects. | Recurrence Score lower than 38: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects. |
| intermediate_risk | Recurrence Score of 39 up to and including 54: The cancer has an intermediate risk of recurrence. It’s unclear whether the benefits of chemotherapy outweigh the risks of side effects. | Recurrence Score of 39 up to and including 54: The cancer has an intermediate risk of recurrence. It’s unclear whether the benefits of chemotherapy outweigh the risks of side effects. |
| high_risk | Recurrence Score greater than or equal to 55: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects. | Recurrence Score greater than or equal to 55: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects. |